Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 578.

https://doi.org/10.1182/blood-2024-200271

Published: 2024

Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 623.

https://doi.org/10.1182/blood-2023-179160

Published: 2023

Journal Articles

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Blood (2022) 140 (Supplement 1): 9665–9667.

https://doi.org/10.1182/blood-2022-159476

Published: 2022

Journal Articles

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

Danielle Fredman, Yulia Volchek, MD, Gabriel Heering, Keren Shichrur, PhD, Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Elena Ribakovsky, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, MD, Jonathan Canaani, MD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134771

Published: 2020

Journal Articles

Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study

Adi Shacham Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, MD, Ilana Hellman, Liat Shargian, Anna Gourevietch, Evgeni Chubar, MD, Roy Ratzon, MD, Uri Rozovski

Blood (2017) 130 (Supplement 1): 5249.

https://doi.org/10.1182/blood.V130.Suppl_1.5249.5249

Published: 2017

Journal Articles

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Ohad Benjamini, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Meirav Kedmi, MD, Adrian Duek, MD, Drorit Merkel, MD, Merav Leiba, MD, Ivetta Danylesko, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, Yulia Volchek, MD

Blood (2016) 128 (22): 5429.

https://doi.org/10.1182/blood.V128.22.5429.5429

Published: 2016

Journal Articles

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Adi Shacham Abulafia, MD, Pia Raanani, MD, David Lavie, MD, Yulia Volchek, MD, Ron Ram, MD, Ilana Hellmann, MD, Liat Shargian, MD, Anna Gourevietch, MD, Evgeni Chubar, MD, Roy Ratzon, BSC, Uri Rozovski, MD

Blood (2015) 126 (23): 5155.

https://doi.org/10.1182/blood.V126.23.5155.5155

Published: 2015

Journal Articles

Missing HLA C Group 1 Ligand In Patients With AML and MDS Is Associated With Reduced Risk Of Relapse After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning

Avichai Shimoni, MD, Massimo Bernardi, MD, Ronit Yerushalmi, MD, Jacopo Peccatori, MD, Noga Shem-Tov, MD, Alessandro Lo Russo, MD, Yulia Volchek, MD, Luca Vago, MD, PhD, Chiara Bonini, MD, Maria Teresa Lupo Stanghellini, MD, Arnon Nagler, MD, MSc, Fabio Ciceri

Blood (2013) 122 (21): 4634.

https://doi.org/10.1182/blood.V122.21.4634.4634

Published: 2013

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later

Avichai Shimoni, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD, MSc

Blood (2013) 122 (21): 4635.

https://doi.org/10.1182/blood.V122.21.4635.4635

Published: 2013

Journal Articles

The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients

Ivetta Danylesko, MD, Rina Sareli, Nira Bloom-Varda, Ronit Yerushalmi, Noga Shem-Tov, MD, Yulia Volchek, MD, Avichai Shimoni, MD, Arnon Nagler, MD, MSc

Blood (2013) 122 (21): 3275.

https://doi.org/10.1182/blood.V122.21.3275.3275

Published: 2013

Journal Articles

Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen

Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ivetta Danylesko, MD, Abraham Avigdor, MD, Arnon Nagler, MD, MSc, Avichai Shimoni

Blood (2013) 122 (21): 3380.

https://doi.org/10.1182/blood.V122.21.3380.3380

Published: 2013

Journal Articles

Assessment of the Effect of Nilotinib (Tasigna) Maintenance Therapy After Allogeneic Stem Cell Transplantation in Patients with Advanced CML and Ph+ ALL On Immune Reconstitution and Lymphocyte Function

Nira Varda-Bloom, Raz Somech, Yulia Volchek, Jacqueline Davidson, Atar Lev, Ronit Yerushalmi, Avichai Shimoni, Arnon Nagler, MD

Blood (2012) 120 (21): 4478.

https://doi.org/10.1182/blood.V120.21.4478.4478

Published: 2012

Journal Articles

A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease

Maya Koren-Michowitz, Avichai Shimoni, Filomena Daraio, Dr, Francesca Crasto, Dr, Roberta Lorenzatti, Dr, Yulia Volchek, Ninette Amariglio, Enrico Gottardi, MD, Giuseppe Saglio, MD, Arnon Nagler, MD

Blood (2012) 120 (21): 1690.

https://doi.org/10.1182/blood.V120.21.1690.1690

Published: 2012

Journal Articles

Treatment of Relapsed AML and MDS After Allogeneic Stem Cell Transplantation: A Second Transplant From a Different Donor May Be the Most Effective Option

Avichai Shimoni, Noga Shem-Tov, Yulia Volchek, Ronit Yerushalmi, Arnon Nagler, MD

Blood (2012) 120 (21): 1963.

https://doi.org/10.1182/blood.V120.21.1963.1963

Published: 2012

Journal Articles

Favorable Outcome in Patients with Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine and Treosulfan As the Preparative Regimen

Ronit Yerushalmi, Avichai Shimoni, Noga Shem-Tov, Yulia Volchek, Abraham Avigdor, Arnon Nagler, MD

Blood (2012) 120 (21): 1934.

https://doi.org/10.1182/blood.V120.21.1934.1934

Published: 2012

Journal Articles

Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.

Maya Koren-Michowitz, Hannah Maayaan, Ronit Yerushalmi, Noga Shem-Tov, Yulia Volchek, Abraham Avigdor, Avichai Shimoni, Arnon Nagler

Blood (2012) 120 (21): 2629.

https://doi.org/10.1182/blood.V120.21.2629.2629

Published: 2012

Journal Articles

Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced

Avichai Shimoni, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler

Blood (2011) 118 (21): 655.

https://doi.org/10.1182/blood.V118.21.655.655

Published: 2011

Journal Articles

Maintenance Therapy with Nilotinib (Tasigna) Post Allogeneic Stem Cell Transplantation (AlloSCT) for Advanced (>CP 1 ) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Arnon Nagler, MD, Yulia Volchek, MD, Nira Bloom, Ph.D, Raz Somech, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD

Blood (2011) 118 (21): 2011.

https://doi.org/10.1182/blood.V118.21.2011.2011

Published: 2011

Journal Articles

Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning,

Avichai Shimoni, MD, Eran Tallis, MD, Noga Shem-Tov, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler

Blood (2011) 118 (21): 4096.

https://doi.org/10.1182/blood.V118.21.4096.4096

Published: 2011

Journal Articles

Allogeneic Stem-Cell Transplantation for AML and MDS with Tresosulfan Compared with Busulfan-Based Regimens; Reduced Toxicity Vs. Reduced Intensity

Avichai Shimoni, MD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler

Blood (2011) 118 (21): 495.

https://doi.org/10.1182/blood.V118.21.495.495

Published: 2011

NARROW

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Missing HLA C Group 1 Ligand In Patients With AML and MDS Is Associated With Reduced Risk Of Relapse After Allogeneic Stem Cell Transplantation With Fludarabine and Treosulfan Reduced Toxicity Conditioning

Allogeneic Hematopoietic Stem-Cell Transplantation In AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: 10 Years Later

The Use Of Tevagrastim (Biosimilar Filgrastim XMO2) For Hematopoietic Stem Cell Mobilization In HLA Matched Sibling Donors For Allogeneic Stem Cell Transplantation To AML/MDS Patients

Favorable Outcome For Patients With Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine Treosulfan, Compared With Other Reduced Intensity Conditioning Regimen

Assessment of the Effect of Nilotinib (Tasigna) Maintenance Therapy After Allogeneic Stem Cell Transplantation in Patients with Advanced CML and Ph+ ALL On Immune Reconstitution and Lymphocyte Function

A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease

Treatment of Relapsed AML and MDS After Allogeneic Stem Cell Transplantation: A Second Transplant From a Different Donor May Be the Most Effective Option

Favorable Outcome in Patients with Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine and Treosulfan As the Preparative Regimen

Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.

Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced

Maintenance Therapy with Nilotinib (Tasigna) Post Allogeneic Stem Cell Transplantation (AlloSCT) for Advanced (>CP 1 ) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Long-Term Survival and Quality of Life Assessment After Allogeneic Stem-Cell Transplantation; Comparable Results Following Myeloablative and Reduced-Intensity Conditioning,

Allogeneic Stem-Cell Transplantation for AML and MDS with Tresosulfan Compared with Busulfan-Based Regimens; Reduced Toxicity Vs. Reduced Intensity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only